C4 Therapeutics announces first patient dosed in Phase 1/2 trial of CFT1946

C4 Therapeutics announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT1946, an orally bioavailable mutant-selective BiDAC degrader for the treatment of BRAF V600 mutant solid tumors. "Dosing the first patient in the CFT1946 Phase 1/2 clinical trial marks the first degrader to enter clinical development to target BRAF-driven cancers. Many of these patients are typically treated with BRAF inhibitors and have few treatment options once resistance emerges," said Adam Crystal, M.D., Ph.D., chief medical officer of C4 Therapeutics. "Preclinically, in in vivo models, CFT1946 has demonstrated deeper and more durable activity than approved BRAF inhibitors, and promising activity in the setting of resistance to BRAF inhibitors. We look forward to advancing CFT1946 for patients with BRAF V600 mutant cancers including non-small cell lung cancer, colorectal cancer, and melanoma." The Phase 1/2 clinical trial will primarily investigate safety, tolerability, and anti-tumor activity, with secondary and exploratory objectives to characterize the pharmacokinetic and pharmacodynamic profile of CFT1946.